v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
Research and development $ 1,062,500 $ 1,062,500 $ 33,333
Costs and expenses:        
Research and development 4,126,529 2,480,764 9,104,634 5,722,196
General and administrative 2,861,421 2,308,926 5,605,616 5,453,936
Total costs and expenses 6,987,950 4,789,690 14,710,250 11,176,132
Loss from operations (5,925,450) (4,789,690) (13,647,750) (11,142,799)
Sale of New Jersey net operating loss & tax credits 1,734,133 1,328,470
Other income/(loss), net 2,866 (1,415) 12,760 66,904
Net loss (5,922,584) (4,791,105) (11,900,857) (9,747,425)
Preferred stock series B accumulated dividends (184,899) (395,799)
Net loss attributable to common shareholders $ (5,922,584) $ (4,976,004) $ (11,900,857) $ (10,143,224)
Net loss available for common shareholders per share – basic and diluted $ (0.03) $ (0.02) $ (0.05) $ (0.05)
Weighted average common shares outstanding:        
Basic and diluted 216,864,526 205,215,259 216,755,261 204,547,251
Other comprehensive loss, net of tax        
Unrealized loss on securities available-for-sale $ (125,242) $ (85,163) $ (608,917) $ (176,929)
Other comprehensive loss, net of tax (125,242) (85,163) (608,917) (176,929)
Comprehensive loss attributable to shareholders $ (6,047,826) $ (4,876,268) $ (12,509,774) $ (9,924,354)

Source